83 related articles for article (PubMed ID: 19801998)
1. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
2. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
5. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
[TBL] [Abstract][Full Text] [Related]
6. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract][Full Text] [Related]
7. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
[TBL] [Abstract][Full Text] [Related]
8. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition.
Park JE; Kirsch K; Lee H; Oliva P; Ahn JI; Ravishankar H; Zeng Y; Fox SD; Kirby SA; Badhwar P; Andresson T; Jacobson KA; Lee KS
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305037120. PubMed ID: 37603740
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation.
Wolfe BA; Takaki T; Petronczki M; Glotzer M
PLoS Biol; 2009 May; 7(5):e1000110. PubMed ID: 19468300
[TBL] [Abstract][Full Text] [Related]
12. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
[TBL] [Abstract][Full Text] [Related]
13. Polo-box domain: a versatile mediator of polo-like kinase function.
Park JE; Soung NK; Johmura Y; Kang YH; Liao C; Lee KH; Park CH; Nicklaus MC; Lee KS
Cell Mol Life Sci; 2010 Jun; 67(12):1957-70. PubMed ID: 20148280
[TBL] [Abstract][Full Text] [Related]
14. Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
Stebbing J; Bullock AJ
Clin Cancer Res; 2024 May; 30(10):2005-2007. PubMed ID: 38470499
[TBL] [Abstract][Full Text] [Related]
15. PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.
Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Thangavel S; Alobaisi K; Diaz R; Begum R; Haqawi W; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Mol Oncol; 2024 Mar; 18(3):691-706. PubMed ID: 38361222
[TBL] [Abstract][Full Text] [Related]
16. Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer.
Gunasekaran P; Hwang YS; Lee GH; Park J; Kim JG; La YK; Park NY; Kothandaraman R; Yim MS; Choi J; Kim HN; Park IY; Lee SJ; Kim MH; Cha-Molstad H; Shin SY; Ryu EK; Bang JK
J Med Chem; 2024 Mar; 67(5):3307-3320. PubMed ID: 38105611
[TBL] [Abstract][Full Text] [Related]
17. Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
Hou L; Song Z; Xu Z; Wu Y; Shi W
Int J Nanomedicine; 2020; 15():1397-1408. PubMed ID: 32184594
[TBL] [Abstract][Full Text] [Related]
18. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.
Nieto-Jiménez C; Alcaraz-Sanabria A; Pérez-Peña J; Corrales-Sánchez V; Serrano-Heras G; Galán-Moya EM; Serrano-Oviedo L; Montero JC; Burgos M; Llopis J; Pandiella A; Ocaña A
Oncotarget; 2017 Mar; 8(12):19478-19490. PubMed ID: 28061448
[TBL] [Abstract][Full Text] [Related]
19. Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.
Qian W; Park JE; Liu F; Lee KS; Burke TR
Bioorg Med Chem; 2013 Jul; 21(14):3996-4003. PubMed ID: 22743087
[TBL] [Abstract][Full Text] [Related]
20. Crystallization and preliminary X-ray diffraction studies on the human Plk1 Polo-box domain in complex with an unphosphorylated and a phosphorylated target peptide from Cdc25C.
García-Alvarez B; Ibañez S; Montoya G
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Apr; 62(Pt 4):372-5. PubMed ID: 16582488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
